Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.

Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, Ruffion A, Crouzet S, Rimokh R, Gillet PG, Freyer G, Vlaeminck-Guillem V.

Eur Urol Oncol. 2019 Oct 29. pii: S2588-9311(19)30136-1. doi: 10.1016/j.euo.2019.08.010. [Epub ahead of print]

PMID:
31676281
2.

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.

Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton S, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M.

Cancers (Basel). 2019 Sep 6;11(9). pii: E1323. doi: 10.3390/cancers11091323.

3.

Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.

Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C, Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L.

Cytometry A. 2019 Sep;95(9):1008-1018. doi: 10.1002/cyto.a.23844. Epub 2019 Jul 31.

PMID:
31364809
4.

Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19.

Plesa A, Labussière-Wallet H, Hayette S, Salles G, Thomas X, Sujobert P.

Haematologica. 2019 Oct;104(10):e487-e488. doi: 10.3324/haematol.2019.225557. Epub 2019 Jun 13. No abstract available.

5.

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Labussière-Wallet H, Nicolini FE, Michallet M, Hayette S, Sujobert P, Plesa A, Balsat M, Paubelle E, Barraco F, Tigaud I, Ducastelle S, Wattel E, Salles G, Thomas X.

Cancers (Basel). 2019 Apr 22;11(4). pii: E570. doi: 10.3390/cancers11040570.

6.

Methylation of tumour suppressor genes associated with thyroid cancer.

Botezatu A, Iancu IV, Plesa A, Manda D, Popa O, Bostan M, Mihaila M, Albulescu A, Fudulu A, Vladoiu SV, Huica I, Dobrescu R, Anton G, Badiu C.

Cancer Biomark. 2019;25(1):53-65. doi: 10.3233/CBM-182265.

PMID:
31006665
7.

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion.

Plesa A, Sujobert P.

Blood. 2019 Apr 18;133(16):1789. doi: 10.1182/blood-2019-01-898619. No abstract available.

PMID:
31000516
8.

Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.

Delage L, Manzoni D, Quinquenet C, Fontaine J, Maarek A, Chabane K, Mosnier I, Hayette S, Callet-Bauchu E, Grange B, Plesa A, Sujobert P.

Haematologica. 2019 Mar;104(3):e114-e116. doi: 10.3324/haematol.2018.203521. Epub 2018 Dec 13. No abstract available.

9.

Helicobacter pylori prevalence and risk factors among children with celiac disease.

Maxim R, Pleşa A, Stanciu C, Girleanu I, Moraru E, Trifan A.

Turk J Gastroenterol. 2019 Mar;30(3):284-289. doi: 10.5152/tjg.2018.18181.

10.

Accurate quantification of fourteen normal bone marrow cell subsets in infants to the elderly by flow cytometry.

Pont J, Souvignet A, Campos L, Plesa A, Bulabois B, Pernollet M, Raskovalova T, Dumestre-Perard C, Cesbron JY, Jacob MC.

Cytometry B Clin Cytom. 2018 Sep;94(5):627-636. doi: 10.1002/cyto.b.21643.

11.

Total donor chimerism with bone marrow GVHD after multivisceral transplantation.

Alcazer V, Eljaafari A, Lebras L, Dubois V, Plesa A, Sobh M, Hot A, Dumortier J, Boillot O, Chambrier C, Michallet M.

Am J Hematol. 2018 Nov;93(11):E372-E374. doi: 10.1002/ajh.25253. Epub 2018 Sep 9. No abstract available.

12.

A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.

Heiblig M, Elhamri M, Thomas X, Plesa A, Raffoux E, Hayette S.

Leuk Res. 2018 Sep;72:7-11. doi: 10.1016/j.leukres.2018.07.017. Epub 2018 Jul 21. No abstract available.

PMID:
30059824
13.

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M.

J Vis Exp. 2018 Mar 26;(133). doi: 10.3791/56976.

PMID:
29630051
14.

High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia.

Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, Salles G, Bertrand Y, Michallet M, Thomas X.

World J Stem Cells. 2017 Dec 26;9(12):227-234. doi: 10.4252/wjsc.v9.i12.227.

15.

Impact-induced changes in source depth and volume of magmatism on Mercury and their observational signatures.

Padovan S, Tosi N, Plesa AC, Ruedas T.

Nat Commun. 2017 Dec 5;8(1):1945. doi: 10.1038/s41467-017-01692-0.

16.

Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.

Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y.

Haematologica. 2017 Dec;102(12):2086-2096. doi: 10.3324/haematol.2015.139162. Epub 2017 Oct 5.

17.

Opsin-Mediated Inhibition of Bacterioruberin Synthesis in Halophilic Archaea.

Peck RF, Pleşa AM, Graham SM, Angelini DR, Shaw EL.

J Bacteriol. 2017 Oct 3;199(21). pii: e00303-17. doi: 10.1128/JB.00303-17. Print 2017 Nov 1.

18.

LINC01101 and LINC00277 expression levels as novel factors in HPV-induced cervical neoplasia.

Iancu IV, Anton G, Botezatu A, Huica I, Nastase A, Socolov DG, Stanescu AD, Dima SO, Bacalbasa N, Plesa A.

J Cell Mol Med. 2017 Dec;21(12):3787-3794. doi: 10.1111/jcmm.13288. Epub 2017 Aug 2.

19.

Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.

Quintela A, Sujobert P, Tigaud I, Hayette S, Ffrench M, Salles G, Thomas X, Plesa A.

Oncol Ther. 2017;5(1):111-118. doi: 10.1007/s40487-017-0041-7. Epub 2017 Feb 9.

20.

Celiac disease: past, present and future - boundless explorations of a disease of modern times.

Maxim R, Trifan A, Plesa A.

J Gastrointestin Liver Dis. 2017 Mar;26(1):92-93. doi: 10.15403/jgld.2014.1121.261.cel. No abstract available.

21.

Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients.

Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C.

PLoS One. 2017 Jan 19;12(1):e0170160. doi: 10.1371/journal.pone.0170160. eCollection 2017.

22.

Delta Hemolysin and Phenol-Soluble Modulins, but Not Alpha Hemolysin or Panton-Valentine Leukocidin, Induce Mast Cell Activation.

Hodille E, Cuerq C, Badiou C, Bienvenu F, Steghens JP, Cartier R, Bes M, Tristan A, Plesa A, Le VT, Diep BA, Lina G, Dumitrescu O.

Front Cell Infect Microbiol. 2016 Dec 12;6:180. doi: 10.3389/fcimb.2016.00180. eCollection 2016.

23.

Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?

Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, Salles G, Wattel E, Thomas X.

Ann Hematol. 2017 Mar;96(3):363-371. doi: 10.1007/s00277-016-2899-0. Epub 2016 Dec 23.

PMID:
28011984
24.

Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.

Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N.

Eur J Haematol. 2017 Apr;98(4):363-370. doi: 10.1111/ejh.12836. Epub 2017 Jan 30.

PMID:
27943415
25.

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia.

Heiblig M, Paubelle E, Plesa A, Geay MO, Manzoni D, Gazzo S, Tigaud I, Callet-Bauchu E, Huet S, Salles G, Thomas X, Hayette S, Sujobert P.

Blood. 2017 Jan 5;129(1):128-131. doi: 10.1182/blood-2016-09-741355. Epub 2016 Nov 8. No abstract available.

PMID:
27827828
26.

This is not an osteoclast.

Plesa A, Sujobert P.

Blood. 2016 Oct 13;128(15):1993. No abstract available.

PMID:
27737848
27.

PLANET TOPERS: Planets, Tracing the Transfer, Origin, Preservation, and Evolution of their ReservoirS.

Dehant V, Asael D, Baland RM, Baludikay BK, Beghin J, Belza J, Beuthe M, Breuer D, Chernonozhkin S, Claeys P, Cornet Y, Cornet L, Coyette A, Debaille V, Delvigne C, Deproost MH, De WInter N, Duchemin C, El Atrassi F, François C, De Keyser J, Gillmann C, Gloesener E, Goderis S, Hidaka Y, Höning D, Huber M, Hublet G, Javaux EJ, Karatekin Ö, Kodolanyi J, Revilla LL, Maes L, Maggiolo R, Mattielli N, Maurice M, McKibbin S, Morschhauser A, Neumann W, Noack L, Pham LB, Pittarello L, Plesa AC, Rivoldini A, Robert S, Rosenblatt P, Spohn T, Storme J-, Tosi N, Trinh A, Valdes M, Vandaele AC, Vanhaecke F, Van Hoolst T, Van Roosbroek N, Wilquet V, Yseboodt M; Planet TOPERS group (see http://iuap-planet-topers.oma.be/partners.php).

Orig Life Evol Biosph. 2016 Nov;46(4):369-384. Epub 2016 Jun 23.

PMID:
27337974
28.

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience.

Heiblig M, Le Jeune C, Elhamri M, Balsat M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Nicolini F, Wattel E, Salles G, Thomas X.

Leuk Lymphoma. 2017 Jan;58(1):110-117. Epub 2016 May 17.

PMID:
27184036
29.

Occurrence of myelodysplasia/acute myeloid leukemia 'on therapy' in two patients with acute promyelocytic leukemia.

Chelghoum Y, Plesa A, Ducastelle S, Elhamri M, Thomas X.

Indian J Cancer. 2016 Jan-Mar;53(1):59-60. doi: 10.4103/0019-509X.180843. No abstract available.

30.

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

Olombel G, Guerin E, Guy J, Perrot JY, Dumezy F, de Labarthe A, Bastie JN, Legrand O, Raffoux E, Plesa A, Wagner-Ballon O, Cornet E, Salaun V, Preudhomme C, Thomas X, Pautas C, Chantepie S, Turlure P, Castaigne S, Dombret H, Feuillard J.

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29. No abstract available.

PMID:
26929274
31.

Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis.

Bleyzac N, Cuzzubbo D, Rénard C, Garnier N, Dubois V, Domenech C, Goutagny MP, Plesa A, Grardel N, Goutelle S, Janoly-Duménil A, Bertrand Y.

Bone Marrow Transplant. 2016 May;51(5):698-704. doi: 10.1038/bmt.2015.350. Epub 2016 Jan 25.

PMID:
26808568
32.

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.

Heiblig M, Elhamri M, Tigaud I, Plesa A, Barraco F, Labussière H, Ducastelle S, Michallet M, Nicolini F, Plesa C, Wattel E, Salles G, Thomas X.

Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016009. doi: 10.4084/MJHID.2016.009. eCollection 2016.

33.

E5HPV16 mRNA EXPRESSION PATTERN ANALYSIS IN PATIENTS WITH CERVICAL LESIONS IN VIRAL STATUS CONTEXT.

Iancu IV, Pleşa A, Botezatu A, Huică I, Stănescu AD, Socolov D, Anton G.

Roum Arch Microbiol Immunol. 2015 Jan-Jun;74(1-2):33-9.

PMID:
26727852
34.

This is not an erythroblast.

Plesa A, Sujobert P.

Blood. 2015 Oct 1;126(14):1729. No abstract available.

PMID:
26697622
35.

Comparative molecular approaches in Prader-Willi syndrome diagnosis.

Botezatu A, Puiu M, Cucu N, Diaconu CC, Badiu C, Arsene C, Iancu IV, Plesa A, Anton G.

Gene. 2016 Jan 10;575(2 Pt 1):353-8. doi: 10.1016/j.gene.2015.08.058. Epub 2015 Sep 1.

PMID:
26335514
36.

Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia.

Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):477-83. doi: 10.1016/j.clml.2015.02.022. Epub 2015 Mar 5.

PMID:
25843415
37.

The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.

Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Béné MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M.

Leuk Res. 2015 Apr;39(4):453-61. doi: 10.1016/j.leukres.2015.01.008. Epub 2015 Jan 25.

PMID:
25675863
38.

Metastatic carcinoid tumor--atypical presentation.

Pleşa A, Sarca E, Maxim R.

Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):1018-23.

PMID:
25581963
39.

Celiac disease: 10-year experience in a Romanian tertiary center.

Maxim R, Pleşa A, Ciortescu I, Gîrleanu I, Stoica O, Trifan AV.

Rev Med Chir Soc Med Nat Iasi. 2014 Oct-Dec;118(4):986-91.

PMID:
25581958
40.

Esophagectomy in esophageal cancer - is there an optimal approach?

Dănilă N, Lupaşcu C, Andronic M, Costache M, Dumitaş O, Plesa A, Blaj M, Apopei O.

Chirurgia (Bucur). 2014 Sep-Oct;109(5):600-3.

41.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2015 Jan;88(1):21-9. doi: 10.1002/cyto.b.21195. Epub 2014 Nov 1.

42.

Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.

Fossat C, Roussel M, Arnoux I, Asnafi V, Brouzes C, Garnache-Ottou F, Jacob MC, Kuhlein E, Macintyre-Davi E, Plesa A, Robillard N, Tkaczuk J, Ifrah N, Dombret H, Béné MC, Baruchel A, Garand R; for the French Multicenter Study Groups for Pediatric and Adult ALL.

Cytometry B Clin Cytom. 2014 Oct 1. doi: 10.1002/cytob.21195. [Epub ahead of print]

43.

Molecular variants of human papilloma virus 16 E2, E4, E5, E6 and E7 genes associated with cervical neoplasia in Romanian patients.

Plesa A, Anton G, Iancu IV, Diaconu CC, Huica I, Stanescu AD, Socolov D, Nistor E, Popa E, Stoian M, Botezatu A.

Arch Virol. 2014 Dec;159(12):3305-20. doi: 10.1007/s00705-014-2199-8. Epub 2014 Aug 21.

PMID:
25143263
44.

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V.

Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1.

45.

Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia.

Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X.

Leuk Lymphoma. 2015 Mar;56(3):622-9. doi: 10.3109/10428194.2014.927453. Epub 2014 Jul 17.

PMID:
24884314
46.

Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia.

Plesa A, Chelghoum Y, Mattei E, Labussière H, Elhamri M, Cannas G, Morisset S, Tagoug I, Michallet M, Dumontet C, Thomas X.

World J Stem Cells. 2013 Oct 26;5(4):196-204. doi: 10.4252/wjsc.v5.i4.196.

47.

Wavelet-based decomposition of high resolution surface plasmon microscopy V(Z) curves at visible and near infrared wavelengths.

Boyer-Provera E, Rossi A, Oriol L, Dumontet C, Plesa A, Berguiga L, Elezgaray J, Arneodo A, Argoul F.

Opt Express. 2013 Mar 25;21(6):7456-77. doi: 10.1364/OE.21.007456.

PMID:
23546129
48.

Bortezomib influences the expression of malignant plasma cells membrane antigens.

Tagoug I, Plesa A, Dumontet C.

Eur J Pharmacol. 2013 Apr 15;706(1-3):11-6. doi: 10.1016/j.ejphar.2013.02.002. Epub 2013 Feb 28.

PMID:
23458070
49.

Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and promoter methylation in cervical oncogenic lesions and cancer.

Botezatu A, Socolov D, Iancu IV, Huica I, Plesa A, Ungureanu C, Anton G.

J Cell Mol Med. 2013 Apr;17(4):543-9. doi: 10.1111/jcmm.12032. Epub 2013 Feb 28.

50.

High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.

Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP, Michallet M.

PLoS One. 2012;7(12):e51527. doi: 10.1371/journal.pone.0051527. Epub 2012 Dec 10.

Supplemental Content

Support Center